White House pulls Trump’s nomination for CDC director hours before confirmation hearing

White House pulls Trump’s nomination for CDC director hours before confirmation hearing


Former Congressman Dave Weldon addresses a small crowd in The Villages, Fla.

Brendan Farrington | AP

The White House has pulled President Donald Trump’s nominee to lead the Centers for Disease Control and Prevention, former Rep. Dave Weldon, the Senate’s Health committee confirmed Thursday.

The move came just hours before the former Florida lawmaker, a vaccine critic, was set to appear before the U.S. Senate Committee on Health, Education, Labor and Pensions for a confirmation hearing.

Axios first reported the decision on Thursday. Robert F. Kennedy, who leads the Department of Health and Human Services, said Weldon wasn’t ready for the role, Axios reported. HHS oversees the CDC and all other federal health agencies.

But Weldon’s views align closely with Kennedy, a notorious vaccine skeptic. Weldon, 71, has long questioned the safety of certain vaccines, promoting the false claim linking vaccines to autism. In 2006, Weldon appeared with parents who claimed that the CDC had covered up evidence tying vaccines to children developing autism.

The CDC will reportedly re-examine that link under Kennedy despite decades of research debunking it.

While in Congress, Weldon sponsored a bill that would transfer responsibility for vaccine safety away from the CDC. He claimed the agency had a conflict of interest because it purchases and promotes vaccines. The bill never made it past committees. 

Weldon is an internal medicine doctor who served in Congress for 14 years, from 1995 to 2009. 

This story is developing. Please check back for updates.



Source

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More